Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus SOLIFENACIN SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus SOLIFENACIN SUCCINATE.
DETROL LA vs SOLIFENACIN SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Category C
Category A/B
Anticholinergic
Anticholinergic